February 13, 2018 08:27 AM EST
R&D

Eli Lil­ly touts PhI­II suc­cess for Taltz as ri­val No­var­tis stays well out front in crowd­ed im­munol­o­gy race

John Carroll

Editor & Founder

The chess pieces are mov­ing again in the block­buster mar­ket­ing game of im­munol­o­gy drugs.

This morn­ing it’s Eli Lil­ly’s $LLY turn to make a move …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

Eli Lil­ly taps Ama­zon Phar­ma­cy to dis­pense its pre­scrip­tion med­i­cines

A service from the Financial Times